# DEXCOM INC (DXCM) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from DEXCOM INC's 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/DXCM/mda/fy2025/): filed 2026-02-12; accession 0001093557-26-000027 (https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/DXCM/mda/fy2024/): filed 2025-02-18; accession 0001093557-25-000036 (https://www.sec.gov/Archives/edgar/data/1093557/000109355725000036/dxcm-20241231.htm)
- [FY 2023 MD&A](/company/DXCM/mda/fy2023/): filed 2024-02-08; accession 0001093557-24-000021 (https://www.sec.gov/Archives/edgar/data/1093557/000109355724000021/dxcm-20231231.htm)
- FY 2022: filed 2023-02-09; accession 0001093557-23-000024 (https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm-20221231.htm); MD&A text quarantined because Item 7 boundaries were low-confidence; no filing narrative is published for this year.
- FY 2021: filed 2022-02-14; accession 0001093557-22-000014 (https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-20211231.htm); MD&A text quarantined because Item 7 boundaries were low-confidence; no filing narrative is published for this year.

Back to /company/DXCM/